Hypothesis\n\nNLRP3 inflammasome activation in thymic epithelial cells (TECs) increases mitochondrial ROS, which suppresses SIRT3 deacetylase activity and leads to hyperacetylation of STAT3 on Lys685. Acetylated STAT3 drives transcription of IL‑6 and the soluble IL‑6 receptor (sIL‑6R), amplifying IL‑6 trans‑signaling. IL‑6 trans‑signaling, via STAT3 phosphorylation, further upregulates NLRP3, ASC and caspase‑1 expression, creating a feed‑forward loop that accelerates TEC senescence and naïve T‑cell loss.\n\n## Mechanistic Model\n\n1. NLRP3 → ROS → SIRT3 inhibition\n Active NLRP3 triggers ASC‑caspase‑1 signaling that damages mitochondrial membranes, raising ROS. ROS oxidizes SIRT3 cofactors, diminishing its deacetylase function.\n\n2. SIRT3 loss → STAT3 acetylation\n With reduced SIRT3, mitochondrial STAT3 accumulates acetyl groups (Lys685). Acetylated STAT3 translocates to the nucleus where it binds promoters of IL6 and IL6R.\n\n3. STAT3ac → IL‑6 trans‑signaling\n Nuclear STAT3ac boosts IL‑6 transcription and also induces ADAM17‑mediated shedding of IL‑6R, increasing sIL‑6R. The IL‑6/sIL‑6R complex activates gp130 on TECs and nearby immune cells, triggering JAK/STAT3 phosphorylation.\n\n4. pSTAT3 → NLRP3 up‑regulation\n Phosphorylated STAT3 binds consensus sites in the NLRP3 and ASC promoters, enhancing their transcription. This raises inflammasome components, completing the loop.\n\n5. Outcome\n Persistent loop drives p16^INK4a^ expression, SA‑β‑gal positivity, and apoptosis of TECs, reducing thymic output of naïve T cells.\n\n## Testable Predictions\n\n- Prediction 1: In aged mice, TECs from NLRP3‑deficient animals will show lower mitochondrial ROS, higher SIRT3 activity, reduced STAT3 Lys685 acetylation, and decreased sIL‑6R levels compared with wild‑type controls.\n- Prediction 2: Expressing a STAT3 K685R (acetylation‑deficient) mutant in TECs will blunt IL‑6 trans‑signaling despite NLRP3 activation, lowering senescence markers.\n- Prediction 3: Pharmacological inhibition of NLRP3 (MCC950) combined with a STAT3 acetylation inhibitor (e.g., cucurbitacin I) will produce a synergistic decrease in TEC senescence and a greater increase in recent thymic emigrants than either treatment alone.\n- Prediction 4: Rapamycin’s beneficial effect on thymic aging will be attenuated in TECs lacking SIRT3, linking mTOR inhibition to SIRT3‑dependent STAT3 deacetylation.\n\n## Experimental Approach\n\n- Generate TEC‑specific NLRP3 floxed mice crossed with Foxn1‑Cre; treat subsets with rapamycin or vehicle.\n- Isolate TECs, measure MitoSOX ROS, SIRT3 activity (fluorometric assay), STAT3 acetyl‑Lys685 (immunoprecipitation‑Western), sIL‑6R (ELISA).\n- Introduce STAT3 WT or K685R via adenoviral transduction into TECs from aged mice; assess IL‑6 transcription (qPCR), senescence (p16, SA‑β‑gal), and co‑culture with thymocytes to quantify naïve CD4+CD8‑ output.\n- Treat aged wild‑type mice with MCC950, cucurbitacin I, or both for 4 weeks; flow‑cytometry for recent thymic emigrants (RTEs: CD45RA+CCR7+CD62L+).\n- Include SIRT3‑conditional knockout TECs to test rapamycin dependence.\n\n## Potential Pitfalls and Alternatives\n\nIf STAT3 acetylation does not change with NLRP3 loss, the ROS‑SIRT3 axis may be irrelevant; alternative pathways such as NF‑κB‑driven IL‑6 transcription should be examined. If combined inhibition fails to show synergy, the loop may be linear rather than circular, suggesting downstream effectors (e.g., mTORC1) dominate.\n\n## Translation\n\nTargeting the NLRP3‑ROS‑SIRT3‑STAT3ac axis with existing inhibitors (MCC950, SIRT3 activators like honokiol, STAT3 acetylation blockers) offers a tractable route to thymic rejuvenation, potentially improving vaccine responsiveness in older adults.